Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosaprepitant versus aprepitant for prevention of cisplatin-induced nausea and vomiting
2007-004043-30Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chemotherapy-induced nausea and vomiting (CINV) comparing Single-dose fosaprepitant regimen with Aprepitant regimen (2 arms). Primary endpoints: Overall complete response and Safety and tolerability. Started Nov 2007; status: completed.
02
Drugs
fosaprepitantaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2007-004043-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004043-30.